Sheila Gujrathi - 05 Nov 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
05 Nov 2024
Net transactions value
$0
Form type
4
Filing time
07 Nov 2024, 19:09:54 UTC
Previous filing
28 Jun 2024
Next filing
26 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Other $0 +4,611 +4.2% $0.000000 115,139 05 Nov 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents receipt of securities in a pro rata, in-kind distribution, and not a purchase of securities, by ABV SPV I GP LLC, of which Reporting Person is a member.